Tirzepatide
⥠Quick Description & Benefits
Dual GIP/GLP-1 receptor agonist. Marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Weekly subcutaneous injection by Eli Lilly.
Key Benefits:
- â Dual action on GIP and GLP-1 receptors â stronger appetite suppression and satiety signaling than GLP-1 alone
- â Average 15-22.5% body weight loss over 72 weeks at highest dose (Zepbound)
- â Significant reduction in HbA1c (up to ~2.0%)
- â Improves triglycerides, blood pressure, and waist circumference
- â Reduces risk of type 2 diabetes progression in obese patients
đŦ Detailed Function & Research
Mechanism & Function
Dual GIP/GLP-1 receptor agonist. Marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Weekly subcutaneous injection by Eli Lilly. It operates by stimulating specific cellular receptors, activating downstream enzymatic pathways and physiological repair mechanisms without widespread systemic disturbance.
Research & Scientific Support
Extensive pre-clinical and translational models demonstrate consistent receptor affinity and regenerative signalling across controlled studies.
Protocol Notes:
- âĸ FDA-approved in 2022 (Mounjaro for T2D) and 2023 (Zepbound for obesity).
- âĸ ~5 day half-life enables once-weekly dosing; steady state reached in ~4-5 weeks.
- âĸ Does NOT stack with Semaglutide or Retatrutide â all target the same GLP-1 pathway. Combining raises side effect risk without added benefit.
- âĸ Grey-market "research" tirzepatide is identical in molecule but unapproved and unverified. Some compounded versions exist under FDA shortage-window legality, which may end once the shortage resolves.
- âĸ Retail cost after insurance often $600-$1,100/month; compounded/telehealth versions usually $200-$500/month.
𧎠Dosing & Reconstitution Calculator
Calculate syringe units or suggest optimal reconstitution solution volume
Volume Guideline: Most subcutaneous injections should fall between 10 and 20 units for optimal comfort, though certain peptides may feel better at volumes up to 60 units. Increments start at 1.0ml in 0.5ml steps.
đ Research Papers & Clinical Studies
Peer-reviewed research and indexed publications for Tirzepatide:
đ Dosing & Administration
Monthly escalation: âĸ Weeks 1-4: 2.5 mg once weekly âĸ Weeks 5-8: 5.0 mg once weekly âĸ Weeks 9-12: 7.5 mg once weekly âĸ Weeks 13-16: 10 mg once weekly âĸ Weeks 17-20: 12.5 mg once weekly âĸ Week 21 onward: 15 mg weekly (maximum maintenance dose) Stay at a dose as long as tolerated before escalating. GI side effects are the dose-limiter.
Same escalation as Zepbound; maximum maintenance 15 mg weekly. Some patients stay at 5-10 mg if glucose is controlled.
đ Pairs Well With
â ī¸ Side Effects
- ! Nausea, diarrhea, vomiting, constipation (dose-dependent, most common)
- ! Abdominal pain, dyspepsia, burping, flatulence
- ! Injection site reactions
- ! Loss of appetite
- ! Rare: pancreatitis, gallbladder disease, severe gastroparesis
- ! Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2